Skip to main content
SpringerLink
Log in

MULTIPLE SCLEROSIS

Classifying silent progression in relapsing–remitting MS

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

A new study suggests that patients with relapsing–remitting multiple sclerosis can experience long-term increases in disability in the absence of disease relapses. Monitoring this ‘silent progression’ will require a paradigm shift in the way disease progression is evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. University of California, San Francisco MS-EPIC Team et al. Silent progression in disease activity–free relapsing multiple sclerosis. Ann. Neurol. 85, 653–666 (2019).

    Article  Google Scholar 

  2. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).

    Article  CAS  Google Scholar 

  3. Fischer, J. S. et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5, 244–250 (1999).

    Article  CAS  Google Scholar 

  4. Goodin, D. S. et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 282–287 (2012).

    Article  Google Scholar 

  5. University of California, San Francisco MS-EPIC Team et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol. 80, 499–510 (2016).

    Article  Google Scholar 

  6. Filippi, M. et al. Gray matter damage predicts the accumulation of disability 13 years later. Neurology 81, 1759–1767 (2013).

    Article  Google Scholar 

  7. Radue, E. W. et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 84, 784–793 (2015).

    Article  Google Scholar 

  8. Kappos, L. et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult. Scler. 22, 1297–1305 (2016).

    Article  Google Scholar 

  9. Lorscheider, J. et al. Defining secondary progressive multiple sclerosis. Brain 139, 2395–2405 (2016).

    Article  Google Scholar 

  10. Rocca, M. A. & Filippi, M. Targeting progression in multiple sclerosis — an update. Nat. Rev. Neurol. 15, 62–64 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroimaging Research Unit and Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi & Maria A. Rocca

  2. Vita-Salute San Raffaele University, Vita-Salute San Raffaele University, Milan, Italy

    Massimo Filippi

Authors
  1. Massimo Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria A. Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Competing interests

M.F. is Editor-in-Chief of the Journal of Neurology; has received compensation for consulting services and/or speaking activities from Biogen, Merck Serono, Novartis and Teva Pharmaceutical Industries; and receives research support from ARiSLA (Fondazione Italiana di Ricerca per la SLA), Biogen, Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, Merck Serono, Novartis, Roche and Teva Pharmaceutical Industries. M.A.R. received speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceutical Industries; and receives research support from Fondazione Italiana Sclerosi Multipla and the Italian Ministry of Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filippi, M., Rocca, M.A. Classifying silent progression in relapsing–remitting MS. Nat Rev Neurol 15, 315–316 (2019). https://doi.org/10.1038/s41582-019-0199-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0199-8

  • Springer Nature Limited

Search

Navigation